Novartis gets Egyptian Drug Authority approval for Kisqali early breast cancer use
Novartis said it received approval from Egypt’s Egyptian Drug Authority for Kisqali as an adjuvant treatment in early-stage breast cancer for adult patients with HR-positive, HER2-negative stage II disease.
Novartis said on Tuesday it has received approval from the Egyptian Drug Authority for a new indication for Kisqali as an adjuvant treatment for adult patients with hormone receptor-positive, human epidermal growth factor receptor-2-negative stage II and I…